Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

@article{Rodig2010CrizotinibAS,
  title={Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.},
  author={Scott J Rodig and Geoffrey I. Shapiro},
  journal={Current opinion in investigational drugs},
  year={2010},
  volume={11 12},
  pages={1477-90}
}
Crizotinib (PF-02341066), under development by Pfizer, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of the receptor tyrosine kinases (RTKs) c-Met (also known as hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK), for the potential treatment of cancers dependent on these oncogenic kinases for growth and survival. Since the first published characterizations of crizotinib only a few years ago, the drug has been extensively validated as a highly specific… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

Similar Papers

Loading similar papers…